SELLAS Life Sciences Gr Analyst Ratings
SELLAS Life Sciences Gr Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/07/2023 | 109.79% | Cantor Fitzgerald | → $3 | Reiterates | Overweight → Overweight |
| 11/15/2022 | 459.44% | Alliance Global Partners | $14 → $8 | Maintains | Buy |
| 06/28/2022 | 319.58% | Cantor Fitzgerald | $10 → $6 | Maintains | Overweight |
| 07/21/2021 | 1158.74% | Cantor Fitzgerald | → $18 | Initiates Coverage On | → Overweight |
| 11/15/2019 | 739.16% | Maxim Group | → $12 | Upgrades | Hold → Buy |
| 04/08/2019 | 214.69% | Alliance Global Partners | → $4.5 | Initiates Coverage On | → Buy |
| 11/01/2018 | 809.09% | Oppenheimer | → $13 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/07/2023 | 109.79% | 康託·菲茨傑拉德 | →$3 | 重申 | 超重→超重 |
| 2022年11月15日 | 459.44% | 聯盟全球合作夥伴 | $14→$8 | 維護 | 買 |
| 2022/06/28 | 319.58% | 康託·菲茨傑拉德 | $10→$6 | 維護 | 超重 |
| 07/21/2021 | 1158.74% | 康託·菲茨傑拉德 | →$18 | 開始承保 | →超重 |
| 2019年11月15日 | 739.16% | Maxim集團 | →$12 | 升級 | 持有→購買 |
| 2019年08月04日 | 214.69% | 聯盟全球合作夥伴 | →$4.5 | 開始承保 | →購買 |
| 2018/11/01 | 809.09% | 奧本海默 | →$13 | 開始承保 | →跑贏大盤 |
What is the target price for SELLAS Life Sciences Gr (SLS)?
Sellas Life Science Gr(SLS)的目標價是多少？
The latest price target for SELLAS Life Sciences Gr (NASDAQ: SLS) was reported by Cantor Fitzgerald on September 7, 2023. The analyst firm set a price target for $3.00 expecting SLS to rise to within 12 months (a possible 109.79% upside). 2 analyst firms have reported ratings in the last year.
坎託·菲茨傑拉德於2023年9月7日報道了塞拉斯生命科學公司(納斯達克：SLS)的最新目標價。這家分析公司將目標價定為3美元，預計SLS將在12個月內升至(可能上漲109.79%)。去年有兩家分析公司公佈了評級。
What is the most recent analyst rating for SELLAS Life Sciences Gr (SLS)?
Sellas Life Science Gr(SLS)的最新分析師評級是多少？
The latest analyst rating for SELLAS Life Sciences Gr (NASDAQ: SLS) was provided by Cantor Fitzgerald, and SELLAS Life Sciences Gr reiterated their overweight rating.
賽拉斯生命科學Gr(納斯達克代碼：SLS)的最新分析師評級由康託·菲茨傑拉德提供，賽拉斯生命科學Gr重申其增持評級。
When is the next analyst rating going to be posted or updated for SELLAS Life Sciences Gr (SLS)?
Sellas Life Science Gr(SLS)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of SELLAS Life Sciences Gr, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for SELLAS Life Sciences Gr was filed on September 7, 2023 so you should expect the next rating to be made available sometime around September 7, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Sellas Life Science Gr的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Sellas Life Science Gr的上一次評級是在2023年9月7日提交的，所以你應該預計下一次評級將在2024年9月7日左右的某個時候提供。
Is the Analyst Rating SELLAS Life Sciences Gr (SLS) correct?
分析師對Sellas Life Science Gr(SLS)的評級正確嗎？
While ratings are subjective and will change, the latest SELLAS Life Sciences Gr (SLS) rating was a reiterated with a price target of $0.00 to $3.00. The current price SELLAS Life Sciences Gr (SLS) is trading at is $1.43, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Sellas Life Science Gr(SLS)評級被重申，目標價在0.00美元至3.00美元之間。Sellas Life Science Gr(SLS)目前的交易價格為1.43美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。